ObesityPOLOBNCT01969968
Lipophilic Organic Polluants and Morbid Obesity
A study testing Lipophilic Organic Polluants dosage in people with Obesity, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
Trial summary
1. To study the kinetics of release after bariatric surgery of selected polluants stored in adipose tissue, looking for clinical and/or predictive factors 2. To test the hypothesis of a deleterious effect of this release on the expected improvement of insulin-resistance and on the liver inflammation. 3. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Obesity
- What is being tested?
- Lipophilic Organic Polluants dosage
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 232 participants
- Where
- 1 siteFrance
- Study dates
- 18 Dec 2013to 19 Sep 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- age 18 to 65 years
- health coverage
- mentally competent
- signed consent form
- stable weight over the last three months
- Non inclusion criteria :
Show all 9Show fewer
- pregnancy
- insulin treated diabetes
- significant weight change over the last three months
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Lipophilic Organic Polluants and Morbid Obesity: Kinetic of the Release and Impact on the Metabolic Syndrome Before and After Bariatric Surgery
- To study the kinetics of release after bariatric surgery of selected polluants stored in adipose tissue, looking for clinical and/or predictive factors
- To test the hypothesis of a deleterious effect of this release on the expected improvement of insulin-resistance and on the liver inflammation.
- To determine the level of contamination of morbidly obese patients, with or without metabolic syndrome, compared to a control, non obese population, with special attention to clinical (age, gender, reproductive history, pregnancy, nursing) and biological parameters (insulin-resistance, inflammation).
Read the detailed description
I- Goals Because of its exponential prevalence and its co-morbidities, obesity, particularly in its most massive forms, has become a public health problem. It is likely that this epidemic be secondary to both genetic and behavioural factors, and also to environmental factors. Specifically, the "obesogen" and "diabetogen" role of several persistant organic polluants (POP) known as endocrine disruptors used in farming or industry has recently been suggested by experimental animal studies and by human epidemiologic studies. Those chemicals are usually lipophilic, are stored in adipose tissue where they bio-accumulate, and are released in the blood stream during the lipolysis that occurs in any weight loss. This weight loss is particularly rapid and important after bariatric surgery, that is proposed as a treatment for morbid obesity usually leading to an improvement of insulin resistance, metabolic syndrome, and diabetes. However, this improvement is not constant, or is less important than would be anticipated for the massive weight loss observed. This raises the question of the importance and of deleterious impact of the blood release of lipophilic POPs on the evolution of metabolic syndrome and the low grade associated inflammation.
In a prospective, multicentric study, we propose to analyse the kinetic of the release of several POPs during rapid and massive weight loss obtained after bariatric surgery. Those POPs have been chosen for their obesogen or diabetogen properties, reported in vitro or in vivo, for their lipophilic nature, and their ubiquitous presence in the home environment and/or into the food chain: bisphenol A (plastics); tributyltin (fungicide, anti-fouling agent or thermic stabilizant); polybrominated diphenyl ethers (PBDE, fire retardants); perchlorated octanoïd acid and its sulphated compounds (PFOA and PFOS, perfluoroalkyls used as surfactant, lubrifiants, and usted in wrappings); and organochorinated compounds such as: PCB153, representing the polychlorinated bisphenyls (electric isolation); hexachlorobenzene (HBC), and several pesticides: DDE, metabolite of DDT, now banned but with a very long half life, hexachlorocyclohexane (HCH), heptachlor, nanochlor and chlordane used in agriculture.
II- Originality and /or new aspect of the project Though suggested by several experimental studies, the role of POP in human obesity remains largely unknown.
There are no or very few papers on the role in humans of the POPs we have selected, but they are supported by animal experimental studies.
The concept of release in the blood stream after weight loss is recent and deserves to be studied.
III- Reasons for the choice of questions (3 maximum) Interest of the results/method to improve knowledge on those questions
- To study the kinetics of release after bariatric surgery of selected polluants stored in adipose tissue, looking for clinical and/or predictive factors
- To test the hypothesis of a deleterious effect of this release on the expected improvement of insulin-resistance and on the liver inflammation.
- To determine the level of contamination of morbidly obese patients, with or without metabolic syndrome, compared to a control, non obese population, with special attention to clinical (age, gender, reproductive history, pregnancy, nursing) and biological parameters (insulin-resistance, inflammation).
IV- Description of the methods/ Calendar The POPs will be measured in serum, urine (for BPA) and in adipose tissue (subcutaneous and visceral) by gas chromatography coupled to mass spectrometry.
Fat mass will be estimated when possible by DEXA (if weight<150 kg), or by impedancemetry, allowing the calculation of an estimated total body burden for each POP (since they are lipophilic, we will multiply the concentration of each chemical in adipose tissue expressed in ng/g of fat by the total estimated body mass of fat).
The number of patients included will be 250 morbidly obese adults, with or without metabolic syndrome (3 out of 5 classical criteria), eligible for bariatric surgery (125 from Nice undergoing gastric bypass, and 125 from Montpellier undergoing sleeve gastrectomy).
Concentrations of polluants will be measured at baseline and 3, 6 and 12 month after bariatric surgery, and at 18 months as well for patients who will undergo abdominoplasty required by their massive weight loss. Baseline concentrations in obese patients will be compared to those measured in 100 controls, matched for age and gender, with a BMI<25.
Insulin resistance will be assessed by HOMA-IR, adiponectine and SHBG, inflammation by us CRP, leptin, interleukin 6, TNF alpha, transaminases, gammaGT, alkalin phosphatase.
The redistribution of POPs in serum and adipose tissue, and the estimation of total body burden will be assessed before and after surgery.
- Conditions
- Obesity
- Being tested
- Lipophilic Organic Polluants dosage
- Medical subject headings
- Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lipophilic Organic Polluants dosageOther
Urinary, blood and fat dosage of Lipophilic Organic Polluants
| Study group | Role | What they receive |
|---|---|---|
| sleeve bariatric surgery | Other | morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy Receives: Other: Lipophilic Organic Polluants dosage |
| morbidly obese adults with by pass surgery | Other | morbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass Receives: Other: Lipophilic Organic Polluants dosage |
| non obese | Other | non obese patients Receives: Other: Lipophilic Organic Polluants dosage |
What is being measured
The primary outcome is the main question the study is designed to answer.
measurement of POPs
Urinary and blood POPs dosage 18 months after bariatric surgery
Measured: 18 months
clinical and biological assessment of metabolic syndrome
blood dosage for clinical and biological assessment of metabolic syndrome including glucose tolerance test 18 months after bariatric surgery
Measured: 18 months after bariatric surgery
Secondary outcomes (2)
Kinetic profiles of POP release within 18 months following bariatric surgery
blood and urinary dosage
Measured: 18 months following bariatric surgery
Total body burden of selected POPs before and after surgery
Total body burden of selected POPs before and after surgery
Measured: before surgery and 18 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Oct 2013 (estimated)
- Study start18 Dec 2013
- Primary completion19 Sep 2017
- Study completion19 Sep 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Centre Hospitalier Universitaire de NiceThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 232 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Patrick FENICHEL, PhD, Principal investigator, Nice University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01969968
- Sponsor's protocol ID
- 12-API-01
- Acronym
- POLOB
- Status last verified
- Nov 2023
- First submitted
- 22 Oct 2013
- Last updated
- 18 Nov 2023
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Lipophilic Organic Polluants and Morbid Obesity: Kinetic of the Release and Impact on the Metabolic Syndrome Before and After Bariatric Surgery
- ClinicalTrials.gov ID
- NCT01969968
- Acronym / sponsor ID
- POLOB / 12-API-01
- Conditions
- Obesity
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 232 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NiceUniversity, hospital or other
- Study start
- 18 Dec 2013 (actual)
- Primary completion
- 19 Sep 2017 (actual)
- Study completion
- 19 Sep 2017 (actual)
- First posted
- 25 Oct 2013 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To study the kinetics of release after bariatric surgery of selected polluants stored in adipose tissue, looking for clinical and/or predictive factors
- To test the hypothesis of a deleterious effect of this release on the expected improvement of insulin-resistance and on the liver inflammation.
- To determine the level of contamination of morbidly obese patients, with or without metabolic syndrome, compared to a control, non obese population, with special attention to clinical (age, gender, reproductive history, pregnancy, nursing) and biological parameters (insulin-resistance, inflammation).
Detailed description
I- Goals Because of its exponential prevalence and its co-morbidities, obesity, particularly in its most massive forms, has become a public health problem. It is likely that this epidemic be secondary to both genetic and behavioural factors, and also to environmental factors. Specifically, the "obesogen" and "diabetogen" role of several persistant organic polluants (POP) known as endocrine disruptors used in farming or industry has recently been suggested by experimental animal studies and by human epidemiologic studies. Those chemicals are usually lipophilic, are stored in adipose tissue where they bio-accumulate, and are released in the blood stream during the lipolysis that occurs in any weight loss. This weight loss is particularly rapid and important after bariatric surgery, that is proposed as a treatment for morbid obesity usually leading to an improvement of insulin resistance, metabolic syndrome, and diabetes. However, this improvement is not constant, or is less important than would be anticipated for the massive weight loss observed. This raises the question of the importance and of deleterious impact of the blood release of lipophilic POPs on the evolution of metabolic syndrome and the low grade associated inflammation.
In a prospective, multicentric study, we propose to analyse the kinetic of the release of several POPs during rapid and massive weight loss obtained after bariatric surgery. Those POPs have been chosen for their obesogen or diabetogen properties, reported in vitro or in vivo, for their lipophilic nature, and their ubiquitous presence in the home environment and/or into the food chain: bisphenol A (plastics); tributyltin (fungicide, anti-fouling agent or thermic stabilizant); polybrominated diphenyl ethers (PBDE, fire retardants); perchlorated octanoïd acid and its sulphated compounds (PFOA and PFOS, perfluoroalkyls used as surfactant, lubrifiants, and usted in wrappings); and organochorinated compounds such as: PCB153, representing the polychlorinated bisphenyls (electric isolation); hexachlorobenzene (HBC), and several pesticides: DDE, metabolite of DDT, now banned but with a very long half life, hexachlorocyclohexane (HCH), heptachlor, nanochlor and chlordane used in agriculture.
II- Originality and /or new aspect of the project Though suggested by several experimental studies, the role of POP in human obesity remains largely unknown.
There are no or very few papers on the role in humans of the POPs we have selected, but they are supported by animal experimental studies.
The concept of release in the blood stream after weight loss is recent and deserves to be studied.
III- Reasons for the choice of questions (3 maximum) Interest of the results/method to improve knowledge on those questions
- To study the kinetics of release after bariatric surgery of selected polluants stored in adipose tissue, looking for clinical and/or predictive factors
- To test the hypothesis of a deleterious effect of this release on the expected improvement of insulin-resistance and on the liver inflammation.
- To determine the level of contamination of morbidly obese patients, with or without metabolic syndrome, compared to a control, non obese population, with special attention to clinical (age, gender, reproductive history, pregnancy, nursing) and biological parameters (insulin-resistance, inflammation).
IV- Description of the methods/ Calendar The POPs will be measured in serum, urine (for BPA) and in adipose tissue (subcutaneous and visceral) by gas chromatography coupled to mass spectrometry.
Fat mass will be estimated when possible by DEXA (if weight<150 kg), or by impedancemetry, allowing the calculation of an estimated total body burden for each POP (since they are lipophilic, we will multiply the concentration of each chemical in adipose tissue expressed in ng/g of fat by the total estimated body mass of fat).
The number of patients included will be 250 morbidly obese adults, with or without metabolic syndrome (3 out of 5 classical criteria), eligible for bariatric surgery (125 from Nice undergoing gastric bypass, and 125 from Montpellier undergoing sleeve gastrectomy).
Concentrations of polluants will be measured at baseline and 3, 6 and 12 month after bariatric surgery, and at 18 months as well for patients who will undergo abdominoplasty required by their massive weight loss. Baseline concentrations in obese patients will be compared to those measured in 100 controls, matched for age and gender, with a BMI<25.
Insulin resistance will be assessed by HOMA-IR, adiponectine and SHBG, inflammation by us CRP, leptin, interleukin 6, TNF alpha, transaminases, gammaGT, alkalin phosphatase.
The redistribution of POPs in serum and adipose tissue, and the estimation of total body burden will be assessed before and after surgery.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| sleeve bariatric surgery | Other | Other: Lipophilic Organic Polluants dosagemorbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing sleeve gastrectomy |
| morbidly obese adults with by pass surgery | Other | Other: Lipophilic Organic Polluants dosagemorbidly obese adults, with or without metabolic syndrome eligible for bariatric surgery undergoing gastric bypass |
| non obese | Other | Other: Lipophilic Organic Polluants dosagenon obese patients |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- age 18 to 65 years
- health coverage
- mentally competent
- signed consent form
- stable weight over the last three months
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lipophilic Organic Polluants dosageUrinary, blood and fat dosage of Lipophilic Organic Polluants | Other | morbidly obese adults with by pass surgery, non obese, sleeve bariatric surgery |
Primary outcome
measurement of POPs
Time frame: 18 months
Urinary and blood POPs dosage 18 months after bariatric surgery
clinical and biological assessment of metabolic syndrome
Time frame: 18 months after bariatric surgery
blood dosage for clinical and biological assessment of metabolic syndrome including glucose tolerance test 18 months after bariatric surgery
2 secondary outcomes
Kinetic profiles of POP release within 18 months following bariatric surgery
Time frame: 18 months following bariatric surgery
Total body burden of selected POPs before and after surgery
Time frame: before surgery and 18 months after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2023.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Patrick FENICHEL, PhD principal investigator
Nice University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lipophilic Organic Polluants dosage in people with Obesity, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
measurement of POPs (time frame: 18 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2023.